A review of human phase 0 (microdosing) clinical trials following the US food and drug administration exploratory investigational new drug studies guidance

International Journal of Pharmaceutical Medicine

Volumn 20, Issue 3, 2006, Pages 159-165

  Lappin, Graham ^a   Garner, R Colin ^a  

^a Xceleron Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIESTROGEN; CYTOCHROME P450 3A4; DIAZEPAM; ERYTHROMYCIN; FLUCONAZOLE; GLYCOPROTEIN P; MIDAZOLAM; TOLBUTAMIDE; TUBERCIDIN; UNCLASSIFIED DRUG; WARFARIN; ZK 253;

AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; METHODOLOGY; MICRODOSING; NONHUMAN; PATIENT PARTICIPATION; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY; TOXICOLOGY; VOLUNTEER;

EID: 33746753305     PISSN: 13649027     EISSN: 13649027     Source Type: Journal    
DOI: 10.2165/00124363-200620030-00002     Document Type: Review

References (29)

1. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003; 2 (3): 233-40
2. EMEA. Position paper on non-clinical safety studies to support clinical trials with a single microdose. Position paper: CPMP/SWP/2599. 2004 Jun [online]. Available from URL: http://www.emea.eu.int/pdfs/human/swp/259902en.pdf [Accessed 2006 Jun 22]
3. Food and Drug Administration, US Department of Health and Human Services. Guidance for industry investigators and reviewers: exploratory IND studies. 2006 Jan. [online]. Available from URL: http://www.fda.gov/cder/guidance/ 7086fnl.htm [Accessed 2006 Jun 22]
4. Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 2004; 58 (6): 601-8
5. Timchalk C. Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids: evidence that the dog is not a relevant species for evaluation of human health risk. Toxicology 2004; 200 (1): 1-19
6. Balani SK, Nagaraja NV, Qian MG, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006; 34 (3): 384-8
7. Lappin G, Garner RC. Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. In: Wilson I, editor. Handbook of analytical separations. Amsterdam: Elsevier, 2003: 331-49
8. Lappin G, Temple S. Radiotracers in drug development. Boca Raton (FL): Taylor and Francis, 2006
9. Lappin GJ, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with five drugs. Clin Pharmacol Ther. In press
10. ICH Topic M3: Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals: ICH step 5. Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. CPMP/ICH/286/95 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ich/028695en.pdf [Accessed 2006 Jun 20]
11. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22 (2): 151-85
12. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3 (8): 711-5
13. Kennedy T. Managing the drug discovery/development interface. Drug Discov Today 1997; 2: 436-44
14. Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37 (1): 1-16
15. MacGowan AP. Role of pharmacokinetics and pharmacodynamics: does the dose matter? Clin Infect Dis 2001; 33 Suppl. 3: S238-9
16. Kautiainen A, Vogel JS, Turteltaub KW. Dose-dependent binding of trichloroethylene to hepatic DNA and protein at low doses in mice. Chem Biol Interact 1997; 106 (2): 109-21
17. Frantz CE, Bangerter C, Fultz E, et al. Dose-response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis 1995; 16 (2): 367-73
18. Turteltaub KW, Felton JS, Gledhill BL, et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci U S A 1990; 87 (14): 5288-92
19. Mauthe RJ, Dingley KH, Leveson SH, et al. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int J Cancer 1999; 80 (4): 539-45
20. Turteltaub KW, Mauthe RJ, Dingley KH, et al. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat Res 1997; 376 (1-2): 243-52
21. Bergstrom M, Grahnen A, Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003; 59 (5-6): 357-66
22. Sandhu P, Vogel JS, Rose MJ, et al. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 2004; 32 (11): 1254-9
23. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006
24. Levy G, Mager DE, Cheung WK, et al. Comparative pharmacokinetics of coumarin anticoagulants L: physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 2003; 92 (5): 985-94
25. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16 (6): 337-64
26. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59 (5): 491-502
27. Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 2002; 87 (3): 277-80
28. Beumer JH, Beijnen JH, Schellens JH. Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 2006; 45 (1): 33-58
29. Pons G, Rey E. Stable isotopes labeling of drugs in pediatric clinical pharmacology. Pediatrics 1999; 104 (3 Pt 2): 633-9